Soleno Therapeutics faces class action over DCCR trial disclosures after 27% stock drop

Reuters07:54

<a href="https://laohu8.com/S/SLNO">Soleno Therapeutics</a> faces class action over DCCR trial disclosures after 27% stock drop

A securities class action lawsuit was filed on behalf of investors who bought Soleno common stock between March 26, 2025 and November 4, 2025. The complaint alleges Soleno misled investors about safety risks and commercial viability tied to its Phase 3 program for diazoxide choline extended-release tablets (DCCR), including concerns about fluid retention. It also cites a Scorpion Capital report published on August 15, 2025, after which Soleno shares fell about 12% over two trading days. The filing says Soleno disclosed on September 10, 2025 that a patient died after taking DCCR, and the stock fell about 19% over two trading days. The complaint further states that after Soleno discussed launch disruption and higher discontinuations on November 4, 2025, the shares dropped about 27% in one day.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603111954PRIMZONEFULLFEED9670529) on March 11, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618502972?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 07:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618502972","market":"nz","top_or_hot":-1,"title":"Soleno Therapeutics faces class action over DCCR trial disclosures after 27% stock drop","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> faces class action over DCCR trial disclosures after 27% stock drop\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A securities class action lawsuit was filed on behalf of investors who bought Soleno common stock between March 26, 2025 and November 4, 2025. The complaint alleges Soleno misled investors about safety risks and commercial viability tied to its Phase 3 program for diazoxide choline extended-release tablets (DCCR), including concerns about fluid retention. It also cites a Scorpion Capital report published on August 15, 2025, after which Soleno shares fell about 12% over two trading days. The filing says Soleno disclosed on September 10, 2025 that a patient died after taking DCCR, and the stock fell about 19% over two trading days. The complaint further states that after Soleno discussed launch disruption and higher discontinuations on November 4, 2025, the shares dropped about 27% in one day.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603111954PRIMZONEFULLFEED9670529) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soleno Therapeutics faces class action over DCCR trial disclosures after 27% stock drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoleno Therapeutics faces class action over DCCR trial disclosures after 27% stock drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 07:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> faces class action over DCCR trial disclosures after 27% stock drop\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A securities class action lawsuit was filed on behalf of investors who bought Soleno common stock between March 26, 2025 and November 4, 2025. The complaint alleges Soleno misled investors about safety risks and commercial viability tied to its Phase 3 program for diazoxide choline extended-release tablets (DCCR), including concerns about fluid retention. It also cites a Scorpion Capital report published on August 15, 2025, after which Soleno shares fell about 12% over two trading days. The filing says Soleno disclosed on September 10, 2025 that a patient died after taking DCCR, and the stock fell about 19% over two trading days. The complaint further states that after Soleno discussed launch disruption and higher discontinuations on November 4, 2025, the shares dropped about 27% in one day.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603111954PRIMZONEFULLFEED9670529) on March 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL1Zlbdy:1","article_id":"2618502972","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618502972","pubTimestamp":1773273266,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A securities class action lawsuit was filed on behalf of investors who bought Soleno common stock between March 26, 2025 and November 4, 2025. The complaint alleges Soleno misled investors about safety risks and commercial viability tied to its Phase 3 program for diazoxide choline extended-release tablets , including concerns about fluid retention. It also cites a Scorpion Capital report published on August 15, 2025, after which Soleno shares fell about 12% over two trading days. The filing says Soleno disclosed on September 10, 2025 that a patient died after taking DCCR, and the stock fell about 19% over two trading days. The complaint further states that after Soleno discussed launch disruption and higher discontinuations on November 4, 2025, the shares dropped about 27% in one day.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4139":"生物科技","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4112":"金融交易所和数据","SLNO":"Soleno Therapeutics","BK4585":"ETF&股票定投概念","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Soleno Therapeutics股价下跌27%后因DCCR试验披露而面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLNO":0.9,"NDAQ":0.9},"content_text":"Soleno Therapeutics faces class action over DCCR trial disclosures after 27% stock drop\n    \n\n        A securities class action lawsuit was filed on behalf of investors who bought Soleno common stock between March 26, 2025 and November 4, 2025. The complaint alleges Soleno misled investors about safety risks and commercial viability tied to its Phase 3 program for diazoxide choline extended-release tablets (DCCR), including concerns about fluid retention. It also cites a Scorpion Capital report published on August 15, 2025, after which Soleno shares fell about 12% over two trading days. The filing says Soleno disclosed on September 10, 2025 that a patient died after taking DCCR, and the stock fell about 19% over two trading days. The complaint further states that after Soleno discussed launch disruption and higher discontinuations on November 4, 2025, the shares dropped about 27% in one day.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603111954PRIMZONEFULLFEED9670529) on March 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618502972","isCrawlerRequest":true}